Financhill
Sell
5

IVVD Quote, Financials, Valuation and Earnings

Last price:
$0.82
Seasonality move :
-40.93%
Day range:
$0.71 - $0.84
52-week range:
$0.35 - $4.74
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.11x
Volume:
2.6M
Avg. volume:
29.5M
1-year change:
-78.55%
Market cap:
$92.4M
Revenue:
--
EPS (TTM):
-$1.96

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IVVD
Invivyd
$13.6M -$0.10 1529.58% -85.08% $6.67
AMGN
Amgen
$8.9B $5.08 8.14% 257.4% $315.95
AMRX
Amneal Pharmaceuticals
$708.1M $0.15 9.69% 125.42% $11.50
PEPG
PepGen
-- -$0.72 -- -19.05% $12.20
PFE
Pfizer
$17.3B $0.46 -3.03% 29.69% $31.32
TRDA
Entrada Therapeutics
$12.9M -$0.66 -80.31% -128.97% $25.43
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IVVD
Invivyd
$0.77 $6.67 $92.4M -- $0.00 0% --
AMGN
Amgen
$317.17 $315.95 $170.4B 42.01x $2.38 2.88% 5.12x
AMRX
Amneal Pharmaceuticals
$8.62 $11.50 $2.7B 101.17x $0.00 0% 0.96x
PEPG
PepGen
$2.35 $12.20 $76.8M -- $0.00 0% --
PFE
Pfizer
$26.05 $31.32 $147.6B 18.48x $0.43 6.49% 2.33x
TRDA
Entrada Therapeutics
$10.81 $25.43 $406.4M 5.66x $0.00 0% 1.98x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IVVD
Invivyd
-- -4.320 -- 1.47x
AMGN
Amgen
91.09% 0.434 43.85% 0.84x
AMRX
Amneal Pharmaceuticals
104.6% 0.481 101.3% 0.81x
PEPG
PepGen
-- -2.752 -- --
PFE
Pfizer
41.92% 0.618 43.87% 0.82x
TRDA
Entrada Therapeutics
-- 2.917 -- 10.73x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IVVD
Invivyd
$8.5M -$62.3M -- -- -670.01% -$41.1M
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
AMRX
Amneal Pharmaceuticals
$262.9M $54.1M -4.58% -587.3% 6.34% $95M
PEPG
PepGen
-- -$24.3M -- -- -- -$19.7M
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B
TRDA
Entrada Therapeutics
-- -$5.9M 18.3% 18.3% -15.69% -$32.2M

Invivyd vs. Competitors

  • Which has Higher Returns IVVD or AMGN?

    Amgen has a net margin of -653.11% compared to Invivyd's net margin of 6.9%. Invivyd's return on equity of -- beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About IVVD or AMGN?

    Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could fall by -0.39%. Given that Invivyd has higher upside potential than Amgen, analysts believe Invivyd is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVVD
    Invivyd
    1 1 0
    AMGN
    Amgen
    9 14 2
  • Is IVVD or AMGN More Risky?

    Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

  • Which is a Better Dividend Stock IVVD or AMGN?

    Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 2.88% to investors and pays a quarterly dividend of $2.38 per share. Invivyd pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios IVVD or AMGN?

    Invivyd quarterly revenues are $9.3M, which are smaller than Amgen quarterly revenues of $9.1B. Invivyd's net income of -$60.7M is lower than Amgen's net income of $627M. Notably, Invivyd's price-to-earnings ratio is -- while Amgen's PE ratio is 42.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 5.12x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
    AMGN
    Amgen
    5.12x 42.01x $9.1B $627M
  • Which has Higher Returns IVVD or AMRX?

    Amneal Pharmaceuticals has a net margin of -653.11% compared to Invivyd's net margin of -4.26%. Invivyd's return on equity of -- beat Amneal Pharmaceuticals's return on equity of -587.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
    AMRX
    Amneal Pharmaceuticals
    35.99% -$0.10 $2.4B
  • What do Analysts Say About IVVD or AMRX?

    Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Amneal Pharmaceuticals has an analysts' consensus of $11.50 which suggests that it could grow by 33.41%. Given that Invivyd has higher upside potential than Amneal Pharmaceuticals, analysts believe Invivyd is more attractive than Amneal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVVD
    Invivyd
    1 1 0
    AMRX
    Amneal Pharmaceuticals
    1 0 0
  • Is IVVD or AMRX More Risky?

    Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amneal Pharmaceuticals has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.898%.

  • Which is a Better Dividend Stock IVVD or AMRX?

    Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amneal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. Amneal Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVVD or AMRX?

    Invivyd quarterly revenues are $9.3M, which are smaller than Amneal Pharmaceuticals quarterly revenues of $730.5M. Invivyd's net income of -$60.7M is lower than Amneal Pharmaceuticals's net income of -$31.1M. Notably, Invivyd's price-to-earnings ratio is -- while Amneal Pharmaceuticals's PE ratio is 101.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 0.96x for Amneal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
    AMRX
    Amneal Pharmaceuticals
    0.96x 101.17x $730.5M -$31.1M
  • Which has Higher Returns IVVD or PEPG?

    PepGen has a net margin of -653.11% compared to Invivyd's net margin of --. Invivyd's return on equity of -- beat PepGen's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
    PEPG
    PepGen
    -- -$0.68 --
  • What do Analysts Say About IVVD or PEPG?

    Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand PepGen has an analysts' consensus of $12.20 which suggests that it could grow by 419.15%. Given that Invivyd has higher upside potential than PepGen, analysts believe Invivyd is more attractive than PepGen.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVVD
    Invivyd
    1 1 0
    PEPG
    PepGen
    3 0 0
  • Is IVVD or PEPG More Risky?

    Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PepGen has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IVVD or PEPG?

    Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PepGen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. PepGen pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVVD or PEPG?

    Invivyd quarterly revenues are $9.3M, which are larger than PepGen quarterly revenues of --. Invivyd's net income of -$60.7M is lower than PepGen's net income of -$22.2M. Notably, Invivyd's price-to-earnings ratio is -- while PepGen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus -- for PepGen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
    PEPG
    PepGen
    -- -- -- -$22.2M
  • Which has Higher Returns IVVD or PFE?

    Pfizer has a net margin of -653.11% compared to Invivyd's net margin of 2.31%. Invivyd's return on equity of -- beat Pfizer's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
    PFE
    Pfizer
    66.74% $0.07 $152.1B
  • What do Analysts Say About IVVD or PFE?

    Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 20.22%. Given that Invivyd has higher upside potential than Pfizer, analysts believe Invivyd is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVVD
    Invivyd
    1 1 0
    PFE
    Pfizer
    6 13 1
  • Is IVVD or PFE More Risky?

    Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

  • Which is a Better Dividend Stock IVVD or PFE?

    Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.49% to investors and pays a quarterly dividend of $0.43 per share. Invivyd pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios IVVD or PFE?

    Invivyd quarterly revenues are $9.3M, which are smaller than Pfizer quarterly revenues of $17.8B. Invivyd's net income of -$60.7M is lower than Pfizer's net income of $410M. Notably, Invivyd's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 2.33x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
    PFE
    Pfizer
    2.33x 18.48x $17.8B $410M
  • Which has Higher Returns IVVD or TRDA?

    Entrada Therapeutics has a net margin of -653.11% compared to Invivyd's net margin of 3.02%. Invivyd's return on equity of -- beat Entrada Therapeutics's return on equity of 18.3%.

    Company Gross Margin Earnings Per Share Invested Capital
    IVVD
    Invivyd
    91.33% -$0.51 $83.2M
    TRDA
    Entrada Therapeutics
    -- $0.03 $428.7M
  • What do Analysts Say About IVVD or TRDA?

    Invivyd has a consensus price target of $6.67, signalling upside risk potential of 763.22%. On the other hand Entrada Therapeutics has an analysts' consensus of $25.43 which suggests that it could grow by 135.22%. Given that Invivyd has higher upside potential than Entrada Therapeutics, analysts believe Invivyd is more attractive than Entrada Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    IVVD
    Invivyd
    1 1 0
    TRDA
    Entrada Therapeutics
    4 0 0
  • Is IVVD or TRDA More Risky?

    Invivyd has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Entrada Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IVVD or TRDA?

    Invivyd has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Invivyd pays -- of its earnings as a dividend. Entrada Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IVVD or TRDA?

    Invivyd quarterly revenues are $9.3M, which are smaller than Entrada Therapeutics quarterly revenues of $37.4M. Invivyd's net income of -$60.7M is lower than Entrada Therapeutics's net income of $1.1M. Notably, Invivyd's price-to-earnings ratio is -- while Entrada Therapeutics's PE ratio is 5.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Invivyd is -- versus 1.98x for Entrada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IVVD
    Invivyd
    -- -- $9.3M -$60.7M
    TRDA
    Entrada Therapeutics
    1.98x 5.66x $37.4M $1.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock